Novartis vs Bayer
A reminder to always substantiate claims in pharma ads
Brexit: International marks, unregistered designs and more
Major step forward for the Unified Patent Court
by Dr. Gisbert Hohagen, Lic. en droit (Paris II/ Assas) and Dr. Philipp Krusemarck
Commission reveals new IP Action Plan: Changes for designs, GIs, data and more
by Alice Anderson and Louise Popple
"Bait and switch" selling: when is it OK to sell competing products?
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
by Alison Dennis and Dr Paul England
Reloaded: How UK supplementary protection certificates will change from 1 January 2021
Russian coronavirus vaccine – approval process in Hungary and the EU
Available in Hungarian
Pharmaceutical patent law in times of crisis: A comparative study – Part 2
by multiple authors
Plus ça change? How UK patents will be affected from 1 January 2021
Why developments in global trade will highlight patent enforcement in the UK and Trans-Pacific countries
by multiple authors
Pharmaceutical patent law in times of crisis: A comparative study – Part 1
by multiple authors